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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of Hodgkin’s disease
Incidence
. The crude incidence of Hodgkin’s disease in the European
Union is 2.2/100 000 per year, the mortality 0.7/100 000 per
year.
Diagnosis
. Pathological diagnosis should be made according to the
World Health Organisation classification from a surgical
specimen i.e. excisional lymph node biopsy, whenever
possible providing enough material for fresh, frozen and
formalin-fixed samples.
. Classical Hodgkin’s disease (cHD) includes nodular scleros-
ing, mixed cellularity, lymphocyte-rich classical and
lymphocyte-depleted subtypes and is distinguished from
lymphocyte-predominant Hodgkin’s disease (LPHD) for
prognostic reasons.
Staging and risk assessment
. Chest X-ray and a CT-scan of the chest and abdomen, and a
bone marrow biopsy are mandatory.
. Staging laparotomy is not recommended [II, A]. As an
option, PET-scan may be considered in addition to the
CT-scan.
. Full blood count, ESR, and blood chemistry including
C-reactive protein, alkaline phosphatase, albumin, and LDH
[II–III, A].
. The staging according to the Ann. Arbor system with men-
tioning of B-symptoms, bulky disease, involvement of the
spleen and extranodal sites is mandatory for evaluation of
the risk for relapse and for choosing the correct treatment.
. Risk assessment is recommended according to the cate-
gories shown in Table 1 [II–III, A].
Treatment plan
. Note: LPHD is an indolent disease with a tendency to recur.
LPHD stage I disease may be treated with involved field
irradiation (30 Gy) only. For recurrent disease aggressive
therapy should be avoided. Rituximab is an option.
. For all other patients a multidisciplinary treatment planning
should be established. The following treatment recommen-
dations apply to patients able to tolerate anthracycline
therapy.
Limited stage patients
. 2–4 cycles of ABVD (or an equivalent regimen) are used in
combination with involved field radiotherapy (30–36 Gy).
Intermediate stage patients
. Four cycles of ABVD (or an equivalent regime) combined
with involved field irradiation (30–36 Gy) [I, A].
Advanced stage patients
. Eight cycles of ABVD (or BEACOPP). Involved field radio-
therapy (30–36 Gy) should be applied only to initially
bulky tumors (> 7.5 cm) or to sites of residual disease after
chemotherapy [I–II, A]. The probable superiority of esca-
lated BEACOPP over ABVD for advanced stages still
requires long-term confirmation from ongoing randomized
trials.
Response evaluation
. To be done after 4 cycles and after the last cycle of chemo-
or chemo-/radiotherapy by physical examination, laboratory
analysis as above, and the same initially abnormal radio-
graphic tests. Patients with incomplete radiological response
should be evaluated for active disease by biopsy or at least
by repeat radiological testing. If available, PET-scan
may identify partial responders at high risk for early relapse
[III, B].
Follow-up
. History and physical exam every 3 months for 1 year, every
6 months for 3 years, then once a year [V, D].
. Laboratory analysis as above and chest X-ray at 6, 12, and
24 months, then as clinically needed in patients suitable for
further therapy [V, D].
. CT-scan and repetition of initially pathologic radiographic
tests once to confirm remission status. Further regular CT-
scans are not recommended except for evaluation of residual
disease.
. Evaluation of thyroid function (TSH) in patients
with irradiation to the neck at 1, 2, and at least at 5 years
[III, A].
. After chest irradiation at premenopausal age, especially at
an age below 25 years, women should be screened for
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secondary breast cancers clinically [III, A] and, after the
age of 40–50 years, by mammography [III, C].
Treatment of Hodgkin’s disease relapsing
after chemotherapy
. Salvage therapy with e.g. DHAP, EPOCH, or Dexa-BEAM
is indicated. If the disease remains chemosensitive, stem
cell collection, high-dose chemotherapy and autologous
stem cell transplantation is indicated for patients with good
performance status.
. Low-intensity treatment including novel single agents
and/or regional radiotherapy may offer good quality of life
for the remaining patients.
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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Table 1.
Limited stage Clinical Stage (CS) I and II without risk factors
Intermediate stage CS I or II with one or more of the following risk factors:
–large mediastinal mass (>1/3 of thoracic width on chest X-ray, >7.5 cm in CT-scan)
–extranodal involvement
–massive involvement of the spleen (diffuse enlargement or > 5 nodules)
–elevated ESR (>30 mm/h for B-stages or >50 mm/h for A-stages)
–extensive lymph node involvement (>_ 3 lymph node areas)
–older age (>60 years) may be an additional risk factor
Advanced stage CS III or IV
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